PM
AQST icon

Penbrook Management’s Aquestive Therapeutics AQST Stock Holding History

Penbrook Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$180K Buy
43,300
+17,735
+69% +$74.6K 0.11% 98
2026
Q1 		$106K Sell
25,565
-16,595
-39% -$67.4K 0.08% 90
2025
Q4 		$272K Sell
42,160
-1,425
-3% -$8.88K 0.19% 77
2025
Q3 		$244K Hold
43,585
– – 0.17% 85
2025
Q2 		$144K Buy
43,585
+21,000
+93% +$60.2K 0.11% 91
2025
Q1 		$65.5K Buy
+22,585
New +$68.4K 0.05% 105

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Penbrook Management's AQST Position: Q2 2026 in Review

Penbrook Management increased its Aquestive Therapeutics (AQST) stake by 69% in Q2 2026, buying an estimated $74.6K and bringing the position to 43,300 shares worth $180K. The position accounts for 0.11% of the portfolio, ranked #98.

Penbrook Management first reported a position in AQST in Q1 2025 and has held it in 6 quarters since. The position peaked at $272K in Q4 2025. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Penbrook Management held 43,300 shares of Aquestive Therapeutics worth $180K as of Q2 2026.
  • Penbrook Management bought 17,735 Aquestive Therapeutics shares in Q2 2026, an estimated $74.6K.
  • Aquestive Therapeutics made up 0.11% of Penbrook Management's portfolio in Q2 2026, its #98 holding.
  • Penbrook Management first reported a position in Aquestive Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Penbrook Management's Aquestive Therapeutics position peaked at $272K in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Penbrook Management's 13F filing for Q2 2026, filed 23 Jul 2026.